Ibex Wealth Advisors bought a new stake in Eli Lilly And Co (NYSE:LLY) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 13,590 shares of the company’s stock, valued at approximately $1,763,000.
Several other large investors also recently added to or reduced their stakes in LLY. Athena Capital Advisors LLC acquired a new position in shares of Eli Lilly And Co in the fourth quarter valued at approximately $26,000. Wakefield Asset Management LLLP acquired a new position in shares of Eli Lilly And Co in the fourth quarter valued at approximately $27,000. Larson Financial Group LLC acquired a new position in shares of Eli Lilly And Co in the fourth quarter valued at approximately $29,000. Ironwood Financial llc acquired a new position in shares of Eli Lilly And Co in the fourth quarter valued at approximately $30,000. Finally, Trust Department MB Financial Bank N A increased its holdings in shares of Eli Lilly And Co by 54.7% in the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after purchasing an additional 82 shares during the period. 84.49% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly And Co stock opened at $114.94 on Wednesday. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50. Eli Lilly And Co has a 1-year low of $80.96 and a 1-year high of $132.13. The company has a market capitalization of $111.03 billion, a P/E ratio of 20.71, a price-to-earnings-growth ratio of 2.03 and a beta of 0.27.
The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Friday, May 17th will be given a dividend of $0.645 per share. The ex-dividend date is Thursday, May 16th. This represents a $2.58 dividend on an annualized basis and a yield of 2.24%. Eli Lilly And Co’s payout ratio is 46.49%.
A number of research analysts have recently issued reports on LLY shares. Cantor Fitzgerald reissued a “buy” rating on shares of Eli Lilly And Co in a report on Monday, February 4th. UBS Group decreased their price target on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research note on Friday, February 8th. Bank of America set a $129.00 price target on Eli Lilly And Co and gave the company a “hold” rating in a research note on Thursday, March 21st. Citigroup set a $124.00 price target on Eli Lilly And Co and gave the company a “hold” rating in a research note on Tuesday, February 26th. Finally, JPMorgan Chase & Co. began coverage on Eli Lilly And Co in a research note on Tuesday, March 12th. They issued an “overweight” rating and a $140.00 price target on the stock. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Eli Lilly And Co presently has an average rating of “Buy” and a consensus target price of $118.83.
In other Eli Lilly And Co news, SVP Christi Shaw sold 7,577 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $117.14, for a total transaction of $887,569.78. Following the sale, the senior vice president now directly owns 500 shares in the company, valued at $58,570. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $131.41, for a total value of $26,939,050.00. Following the sale, the insider now owns 116,814,018 shares in the company, valued at $15,350,530,105.38. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 870,959 shares of company stock worth $109,672,752. 0.11% of the stock is owned by company insiders.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
See Also: Balance Sheet
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.